Natalizumab treatment reduces fatigue in multiple sclerosis
Posted: Thu Apr 11, 2013 1:04 am
Fatigue is a significant symptom in multiple sclerosis (MS) patients. First-generation disease modifying therapies (DMTs) are at best moderately effective to improve fatigue.
Observations from small cohorts have indicated that natalizumab, an antibody targeting VLA-4, may reduce MS-related fatigue. The TYNERGY study aimed to further evaluate the effects of natalizumab treatment on MS-related fatigue...... Read More - http://www.ms-uk.org/index.cfm/tysabri
Observations from small cohorts have indicated that natalizumab, an antibody targeting VLA-4, may reduce MS-related fatigue. The TYNERGY study aimed to further evaluate the effects of natalizumab treatment on MS-related fatigue...... Read More - http://www.ms-uk.org/index.cfm/tysabri